ULTRAGENYX PHARMACEUTICAL INC. Operating Leases, Rent Expense
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Operating Leases, Rent Expense of $6.40 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2021-02-12
- ULTRAGENYX PHARMACEUTICAL INC. operating leases, rent expense for fiscal 2018 was $6.40M, a 42.22% increase from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. operating leases, rent expense for fiscal 2017 was $4.50M.
| Period end | Operating Leases, Rent Expense 12 month |
|---|---|
| 2018-12-31 | $6.40M 10-K · filed 2021-02-12 |
| 2017-12-31 | $4.50M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |